• Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Cooperative Group.
Auteur:Paridaens, R.; Roy, J A; Nooij, Marianne; Klijn, J; Houston, S; Beex, Louk; Vinholes, J; Tomiak, E; Van Vreckem, Ann; Langenaeken, C; van Glabbeke, Martine; Piccart-Gebhart, Martine
Informations sur la publication:Anti-cancer drugs, 9, 1, page (29-35)
Statut de publication:Publié, 1998-01
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Adult
Aged, 80 and over
Antineoplastic Agents -- adverse effects
Antineoplastic Agents -- therapeutic use
Aromatase Inhibitors
Breast Neoplasms -- drug therapy
Enzyme Inhibitors -- adverse effects
Enzyme Inhibitors -- therapeutic use
Estrogen Antagonists -- therapeutic use
Hot Flashes -- chemically induced
Middle Aged
Nausea -- chemically induced
Tamoxifen -- therapeutic use
Triazoles -- adverse effects
Triazoles -- therapeutic use
Note générale:Clinical Trial
Clinical Trial, Phase II
Comparative Study
Journal Article
Multicenter Study